NORMA Contract Research Organisation for Clinical Trials

NORMA conducts clinical trials, phase I–IV, for international pharmaceutical and biotech companies, through a network of subsidiaries in the Nordic and Baltic countries.

Contract research organisation for clinical trials in northern Europe

We work together as an enthusiastic and service-orientated team to deliver outstanding work. Our flexibility and professionalism have earned us recognition among our clients and is reflected in substantial repeat business.

A recent survey of customer perception among our large customers showed that ‘high quality’ and ‘flexibility’ are the primary reasons for choosing NORMA as their monitoring company. In additon, ‘project team devoted to study’ and ‘geographic reach / presence’ are important factors.

The working climate at NORMAS’s offices is positive and friendly and we strive to keep a low staff turnover.

CRO for clinical trials in various therapeutic areas

NORMA has over 90 employees, including experienced project managers, clinical research associates and clinical trials assistants. NORMA has 19 years of experience and has participated in more than 300 clinical trials across a wide range of therapeutic areas, including:

  • Cardiovascular disorders: AMI, angina pectoris, hypertension, PAD and ACS
  • CNS: depression, schizophrenia, Alzheimer’s dementia, epilepsy, MS, Parkinson’s disease and pain
  • Dermatology: psoriasis and PLE / PMLE
  • Endocrinology: diabetes, HRT, oral contraceptives and osteoporosis
  • Infection: HIV, vaccines and herpes zoster
  • Gastrointestinal disorders: ulcerative colitis, Crohn’s disease and collagenous colitis
  • Oncology: breast cancer, prostate cancer, head-and-neck, leukaemia, solid tumours and malignant melanoma
  • Immunology: arthritis and osteoarthrosis
  • Medical devices: cardiac stents, urethral catheters and suction bags

NORMA has a strong client base with 80% repeat business due to a high level of quality. NORMA has a vast and valid network of potential investigators, and is a flexible and co-operative business partner.

Contract research services for clinical trials

NORMA staff work according to client or NORMA SOPs:

  • Recruitment and evaluation of investigators
  • GCP training of investigators and site staff
  • Submissions to medicines agencies and ethics committees
  • Organisation of investigator meetings
  • Protocol writing
  • CRF design
  • Translations
  • Regular monitoring of phase I-IV trials
  • Reporting to sponsor
  • Medical monitoring
  • Outsourcing of CRAs and CTAs

Contact NORMA

NORMA covers the entire Nordic and Baltic region in northern Europe, with offices in Denmark, Finland, Norway, Sweden, Estonia and Lithuania.

All these countries follow the general EU guidelines for approval of clinical trials; however, there are additional national – or even local – guidelines to follow. The local offices work competently and efficiently according to guidelines to meet and surpass client expectations.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Linn Liljeström Zeuthen Appointed Managing Director for NORMA

Linn Liljeström Zeuthen MSc has been appointed managing director for NORMA. For the last two years Linn has worked as contract manager across all of NORMA's six units. She succeeds NORMA's founder Minga Liljeström who will remain closely involved with NORMA as chairwoman of th

Address
NORMA Denmark

Slotsmarken 11

2970 Horshølm

Other

Denmark

www.norma-cro.com

NORMA Images

Products and Services

Video

White Papers

Related Projects



Afinitor Disperz (everolimus) for the Treatment of TSC-Associated Partial-Onset Seizures



Afinitor Disperz® (everolimus) is indicated for the treatment of tuberous sclerosis complex (TSC) associated partial-onset seizures in adult and paediatric patients.

14 June 2018

Lucemyra (lofexidine) for the Management of Opioid Withdrawal Symptoms



Lucemyra™ (lofexidine) is a non-opioid medication indicated for the mitigation of opioid withdrawal symptoms.

25 May 2018

Fasenra (benralizumab) for the Treatment of Asthma



Fasenra (benralizumab) is a monoclonal antibody (mAb) indicated for the treatment of severe eosinophilic asthma in patients aged 12 years and older.

27 March 2018

Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease



Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

15 December 2017

Sublocade™ for the Treatment of Opioid Use Disorder



Sublocade™ (buprenorphine extended-release) is a partial agonist indicated for the treatment of moderate-to-severe opioid use disorder (OUD) in adults.

11 December 2017

Aliqopa (copanlisib) for the Treatment of Relapsed Follicular Lymphoma



Aliqopa (copanlisib) is a novel intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).

22 September 2017

Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia



Kymriah (tisagenlecleucel) is the first chimeric antigen receptor T cell (CAR-T) therapy approved in the US for the treatment of paediatric and young adult patients with B-cell precursor acute lymphoblastic leukaemia (ALL).

12 September 2017

Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection



Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six.

27 July 2017

Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections



Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Ligand Pharmaceuticals.

6 July 2017

Truxima (rituximab) for the Treatment of Cancer



ruxima™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well as granulomatosis with polyangiitis and microscopic polyangiitis.

8 June 2017

Press Release

15 December 2009

Linn Liljeström Zeuthen MSc has been appointed managing director for NORMA. For the last two years Linn has worked as contract manager across all of NORMA's six units. She succeeds NORMA's founder Minga Liljeström who will remain closely involved with NORMA as chairwoman of th

Read more
14 October 2009

NORMA has been appointed a gazelle company 2009 by Greens Analysis Institute in collaboration with the daily newspaper Borsen and Soliditet in Denmark. A gazelle company is the name given to a company that is among the most rapidly growing in Denmark. It is characterised by a positive g

Read more

Regional Offices

NORMA Denmark

Slotsmarken 11

2970 Horshølm

Other

Denmark

www.norma-cro.com
NORMA Norway

Ullernchausséen 119

N-0284 Oslo

Other

Norway

+47 6752 5800 +47 6752 5801
NORMA Lithuania

J. Galvydzio 3, Room 108

08236 Vilnius

Other

Lithuania

+370 5 27 45 47 5 +370 5 27 45 47 6
NORMA Sweden

Hemvärnsgatan 15, 10 tr.

171 54 Solna

Other

Sweden

+46 8 5620 0451 +46 8 296 721
NORMA Finland

Rajatorpantie 41 C

01640 Vantaa

Other

Finland

+358 9 8520 2140 +358 9 8520 2145
NORMA Estonia

Betooni 9

Tartu 51014

Other

Estonia

+372 7307 827 +372 7307 828

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.